Patni family launches Raay Neo Pharma, targeting Tier 2/3 cities with 15-20% cheaper generics
Third-generation Patnis enter branded generics with a Tier 2/3 city play across UP, Bihar, MP, Jharkhand, Odisha and Maharashtra. Pricing undercuts incumbents by 15-20%, with ₹20-50 crore facility spend, ₹80 crore revenue targeted by FY27 and a ₹1,000 crore ambition in five years ahead of an eventual listing.
What happened
Patni family's third generation launches Raay Neo Pharma, a branded generics venture targeting Tier 2/3 cities with 15-20% lower prices, aiming for ₹80 crore by
Key facts
- 15-20% lower pricing
- ₹20-50 crore facility budget
- ₹80 crore revenue by March 2027
- ₹1,000 crore in 5 years
- 10-12% industry growth
- 10 therapies
Why this matters
Raay Neo signals another family-backed entrant crowding the branded generics mid-market, worth tracking as a potential acquisition target or partnership for incumbents needing Hindi-belt depth before its IPO window opens.